The FDA advisory panel that just dissed Acomplia, Sanofi-Aventis's weight-loss drug, dealt an indirect blow to a frequent and outspoken critic of the drug industry.
Adverse effects include dizziness, nausea, anxiety, depressed mood and headaches and were found to be at 9.4 percent for those on Acomplia and 2.1 percent for those on placebo.